Keefe, Bruyette & Woods upgraded shares of HIVE Blockchain Technologies (CVE:HIV – Free Report) to a moderate buy rating in a research report sent to investors on Wednesday morning,Zacks.com reports.
A number of other brokerages have also commented on HIV. Northland Capmk upgraded shares of HIVE Blockchain Technologies to a “strong-buy” rating in a report on Thursday, September 19th. Cantor Fitzgerald raised HIVE Blockchain Technologies to a “strong-buy” rating in a research report on Tuesday, October 29th. Finally, Roth Capital upgraded shares of HIVE Blockchain Technologies to a “strong-buy” rating in a report on Wednesday, December 18th. Four analysts have rated the stock with a strong buy rating, According to MarketBeat.com, HIVE Blockchain Technologies has a consensus rating of “Strong Buy”.
Check Out Our Latest Research Report on HIV
HIVE Blockchain Technologies Price Performance
See Also
- Five stocks we like better than HIVE Blockchain Technologies
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Airline Stocks – Top Airline Stocks to Buy Now
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Insider Trading – What You Need to Know
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for HIVE Blockchain Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HIVE Blockchain Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
